- Home
- MIRM vs PSNY Comparison
MIRM vs PSNY Comparison
Compare MIRM & PSNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- PSNY
- Stock Information
- Founded
- MIRM 2018
- PSNY 2017
- Country
- MIRM United States
- PSNY Sweden
- Employees
- MIRM N/A
- PSNY N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- PSNY Auto Manufacturing
- Sector
- MIRM Health Care
- PSNY Consumer Discretionary
- Exchange
- MIRM Nasdaq
- PSNY Nasdaq
- Market Cap
- MIRM 1.9B
- PSNY 2.1B
- IPO Year
- MIRM 2019
- PSNY N/A
- Fundamental
- Price
- MIRM $39.10
- PSNY $1.01
- Analyst Decision
- MIRM Strong Buy
- PSNY Hold
- Analyst Count
- MIRM 11
- PSNY 7
- Target Price
- MIRM $58.55
- PSNY $1.29
- AVG Volume (30 Days)
- MIRM 476.2K
- PSNY 3.7M
- Earning Date
- MIRM 05-07-2025
- PSNY 03-06-2025
- Dividend Yield
- MIRM N/A
- PSNY N/A
- EPS Growth
- MIRM N/A
- PSNY N/A
- EPS
- MIRM N/A
- PSNY N/A
- Revenue
- MIRM $336,888,000.00
- PSNY $2,046,740,000.00
- Revenue This Year
- MIRM $29.51
- PSNY N/A
- Revenue Next Year
- MIRM $20.27
- PSNY $77.28
- P/E Ratio
- MIRM N/A
- PSNY N/A
- Revenue Growth
- MIRM 80.76
- PSNY N/A
- 52 Week Low
- MIRM $23.14
- PSNY $0.61
- 52 Week High
- MIRM $54.23
- PSNY $1.94
- Technical
- Relative Strength Index (RSI)
- MIRM 34.64
- PSNY 47.48
- Support Level
- MIRM $37.83
- PSNY $0.98
- Resistance Level
- MIRM $40.32
- PSNY $1.05
- Average True Range (ATR)
- MIRM 2.47
- PSNY 0.08
- MACD
- MIRM -0.33
- PSNY 0.00
- Stochastic Oscillator
- MIRM 25.14
- PSNY 68.00
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About PSNY Polestar Automotive Holding UK PLC ADS
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market-leading standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from USA.